Bottom Line Up Front
Hip osteoarthritis is the second most common MSC therapy application after knees. Image-guided MSC injection into the hip joint costs $4,000–$8,000 in Colombia. Published data shows meaningful pain reduction in 65–80% of patients with mild-to-moderate OA. The treatment may delay but not necessarily prevent hip replacement in patients with advancing disease.
Evidence Level: Level 2–3
Similar quality evidence to knee OA, though with fewer published studies. Comparative studies and case series show consistent pain reduction and functional improvement in appropriate candidates.
Hip OA affects millions of adults and progressively limits mobility, exercise capacity, and quality of life. The conventional endpoint is total hip arthroplasty (replacement) — an effective surgery, but one that many patients want to delay as long as possible, particularly if they are active and under 65.
MSC therapy for hip OA follows the same biological principles as knee treatment: anti-inflammatory paracrine effects, immune modulation, and potential slowing of cartilage degradation. The technical difference is that hip injections require fluoroscopic or ultrasound guidance for accurate joint access, as the hip joint is deeper and more difficult to access than the knee.
Trying to Delay Hip Replacement?
An honest assessment of whether MSC therapy could buy you meaningful time before surgery.
Get Free Consultation